Innovative Drug Testing Solutions Seek FDA Approval for Growth

Intelligent Bio Solutions and SMARTOX Partnership
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leading medical technology company, is making significant strides in the U.S. forensic market. Through a strategic partnership with SMARTOX, a recognized leader in drug and alcohol screening, the company is enhancing the availability of its innovative fingerprint drug screening systems. This collaboration focuses on addressing the growing demand for rapid, non-invasive testing methods that can be integrated into various forensic settings.
Growing Demand for Non-Invasive Testing
As awareness of the benefits of non-invasive drug testing solutions increases, SMARTOX has successfully deployed over 50 of INBS's Intelligent Fingerprinting Drug Screening Readers. The partnership has facilitated more than 7,000 screening tests, including over 1,500 just this year, showcasing the drastic need for quicker and more reliable testing options in environments such as corrections, drug courts, and rehabilitation centers.
Efficiency and User Experience Improvement
INBS's innovative technology significantly reduces the need for traditional invasive methods, like urine or saliva collection, which can impact the overall testing experience negatively. The fingerprint-based system delivers results promptly and accurately, linking outcomes directly to the individual tested. Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions, emphasizes that the company aims to transform the landscape of drug testing through effective, non-invasive technology.
Regulatory Path Towards Expansion
Continuing its commitment to innovation, INBS is actively pursuing FDA clearance for its opiate test system for codeine to further tap into the U.S. market. This clearance will facilitate the implementation of its testing technology across various sectors, including workplace environments. The ability to perform fingerprint sweat analysis opens new avenues in drug testing beyond the forensic market, allowing for broader applications.
Why SMARTOX Stands Out
SMARTOX's reputation for excellence lies in its customer-focused approach and commitment to technology. With solutions encompassing DOT compliance, instant and lab-based testing, the partnership with INBS represents a stride towards hygienic, efficient drug screening conducted in under ten minutes. Several clients have noted improvements in operational processes, emphasizing the system's speed, ease of use, and its ability to maintain user dignity while eliminating logistical burdens.
About the Companies
Founded in 2012, SMARTOX has established itself as a comprehensive provider of drug and alcohol testing services, catering to a wide array of sectors including healthcare, corporate environments, justice, and education. The company is dedicated to offering integrated services that encapsulate customer service and administrative support, thereby enhancing client experiences.
For Intelligent Bio Solutions, the future promises exciting developments. As a pioneering medical technology company involved in delivering rapid and non-invasive testing solutions, its aspirations for broader applications of the Intelligent Fingerprinting Drug Screening System are noteworthy. This system, capable of screening for the recent use of drugs such as opiates, cocaine, and cannabis, is particularly beneficial for industries that prioritize safety.
In a market that increasingly calls for efficient, dignified testing methods, Intelligent Bio Solutions (NASDAQ: INBS) is on the cusp of a significant transformation in the drug testing landscape, making it a company to watch.
Frequently Asked Questions
What is the focus of the partnership between Intelligent Bio Solutions and SMARTOX?
The partnership centers on expanding access to Intelligent Bio Solutions' fingerprint drug screening systems within forensic settings, enhancing rapid and non-invasive drug testing.
How many screening tests have been conducted with the Intelligent Fingerprinting system?
Over 7,000 screening tests have been conducted using the Intelligent Fingerprinting Drug Screening Readers, demonstrating a growing demand for non-invasive testing.
What is the significance of FDA clearance for Intelligent Bio Solutions?
FDA clearance is essential for Intelligent Bio Solutions to expand its services into workplace drug testing and broader U.S. markets using its fingerprint sweat analysis technology.
What industries can benefit from Intelligent Bio Solutions' technology?
Industries such as construction, manufacturing, transportation, and drug treatment organizations can benefit significantly from the hygienic and rapid drug testing solutions provided by Intelligent Bio Solutions.
What is SMARTOX's role in the forensic market?
SMARTOX plays a crucial role by deploying INBS's drug screening systems across forensic settings, thereby enhancing traditional drug testing methods with innovative solutions.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.